propafenone has been researched along with Long QT Syndrome in 9 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up." | 2.73 | Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007) |
| "Propafenone is an antiarrhythmic drug metabolized primarily by cytochrome P450 2D6 (CYP2D6)." | 1.72 | Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population. ( Fish, FA; Gaedigk, A; Kannankeril, PJ; Radbill, AE; Sunthankar, SD; Van Driest, SL, 2022) |
| "Mirtazapine is a commonly prescribed antidepressant drug, which is also metabolized through and may modulate the CYP4502D6 pathway leading to altered metabolism of propafenone and possible adverse effects." | 1.40 | Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction. ( Aryal, SR; Khan, MA; Rajpurohit, N; Stys, AT; Stys, TP, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Sunthankar, SD | 1 |
| Kannankeril, PJ | 1 |
| Gaedigk, A | 1 |
| Radbill, AE | 1 |
| Fish, FA | 1 |
| Van Driest, SL | 1 |
| Gagloeva, DA | 1 |
| Dzaurova, KM | 1 |
| Zelberg, MA | 1 |
| Mironov, NY | 1 |
| Yuricheva, YA | 1 |
| Sokolov, SF | 1 |
| Golitsyn, SP | 1 |
| Tomcsányi, J | 1 |
| Tomcsányi, K | 1 |
| Marano, M | 1 |
| Goffredo, BM | 1 |
| Pisani, M | 1 |
| Filippelli, S | 1 |
| Cecchetti, C | 1 |
| Drago, F | 1 |
| Barbieri, MA | 1 |
| Nunziata, J | 1 |
| Genuini, L | 1 |
| Di Nardo, M | 1 |
| Rajpurohit, N | 1 |
| Aryal, SR | 1 |
| Khan, MA | 1 |
| Stys, AT | 1 |
| Stys, TP | 1 |
| Avci, A | 1 |
| Yilmaz, A | 1 |
| Celik, M | 1 |
| Demir, K | 1 |
| Keles, F | 1 |
| Darbar, D | 1 |
| Roden, DM | 1 |
| Lehtonen, A | 1 |
| Fodstad, H | 1 |
| Laitinen-Forsblom, P | 1 |
| Toivonen, L | 1 |
| Kontula, K | 1 |
| Swan, H | 1 |
| Mykytsey, A | 1 |
| Bauman, JL | 1 |
| Razminia, M | 1 |
| Zheutlin, T | 1 |
| Wang, T | 1 |
| Saleem, M | 1 |
| Leal, S | 1 |
| Kehoe, RF | 1 |
1 review available for propafenone and Long QT Syndrome
| Article | Year |
|---|---|
Pharmacogenetics of antiarrhythmic therapy.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Arylamine N-Acetyltransferase; ATP Binding Cassette Tr | 2006 |
1 trial available for propafenone and Long QT Syndrome
| Article | Year |
|---|---|
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut | 2007 |
7 other studies available for propafenone and Long QT Syndrome
| Article | Year |
|---|---|
Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population.
Topics: Adolescent; Adult; Alleles; Anti-Arrhythmia Agents; Child; Child, Preschool; Cytochrome P-450 CYP2D6 | 2022 |
Early initiation of anti-relapse antiarrhythmic therapy in patients with atrial fibrillation and flutter after pharmacological cardioversion with refralon.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Electric Countershock; Humans; Long QT | 2023 |
Wide QRS alternans caused by propafenone toxicity.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Electrocardiography; Female; Heart Rate; Humans; Long QT | 2019 |
Pediatric extracorporeal cardiopulmonary resuscitation settled in an emergency department for a propafenone intentional intoxication.
Topics: Adolescent; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Electrocardiography; Emergency Se | 2018 |
Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine: a case of severe drug interaction.
Topics: Aged; Anti-Arrhythmia Agents; Antidepressive Agents, Tricyclic; Atrial Fibrillation; Bradycardia; Di | 2014 |
Successful treatment of suicide attempt by megadose of propafenone and captopril.
Topics: Adolescent; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; | 2013 |
Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; DNA Mutational Analysis; Electrocardiog | 2007 |